



NYSE Euronext welcomes AB SCIENCE to its European market

-- NYSE Euronext leads Europe in capitalization for listed biotech companies --

Paris, 26 April 2010 – AB SCIENCE, a pharmaceutical company specializing in the discovery, development and sale of tyrosine kinase inhibitors, today celebrated its listing on NYSE Euronext in Paris (mnemo: AB).

AB SCIENCE offers a new class of therapeutic compounds used in the treatment of cancerous tumors, chronic inflammatory diseases and neurodegenerative diseases in human and animal health. Based in Paris, the company has 71 employees and extensive research and development capabilities for its products, enabling it to pursue development of molecules up to registration. AB SCIENCE has chosen to focus on Europe and the United States, markets that together account for nearly two-thirds of revenues generated by a drug.

The admission of AB SCIENCE was by the listing of 29,925,854 existing shares making up its share capital and the issue of 1,305,700 new shares as part of a global offering¹. A further 864,394 existing shares were sold by current shareholders after exercising partially the Extension Option. The total amount raised was EUR 27.5 million.

The admission and issue price of AB SCIENCE shares was set at EUR 12.65 each. The company's capitalization on the day of admission amounted to EUR 379 million.

"We are delighted to welcome AB SCIENCE to our European market and contribute to the emergence of biotechnology as a leading-edge industry," commented Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. *"With capitalization of biotech companies listed on NYSE Euronext totalling EUR 5.1 billion², our market is now the benchmark for innovative companies, offering them exceptional visibility in the financial community and remarkable opportunities for growth."*

Alain Moussy, CEO of AB SCIENCE, added: *"We are very happy with our company's successful listing, and we want to thank all of the European institutional and individual shareholders who have joined us in this ambitious effort. By listing, we have raised the funds we need to start up new Phase 3 clinical studies for our flagship molecule masitinib in human medicine (multiple myeloma, multiple sclerosis, Alzheimer's disease, rheumatoid arthritis and severe asthma), and thus pursue the mission that has driven us from the start: delivering targeted therapies that can dramatically improve quality of life for patients suffering from cancer, neurodegenerative disorders and inflammatory diseases."*

¹ A global offering consists of a public offering (open-price offering) and a global placement with institutional investors in France and abroad.

² Source: NYSE Euronext as of March 31st, 2010.

Press contacts:

NYSE Euronext (Paris) - Tel: +33 (0)1 49 27 11 33

AB SCIENCE

Citigate Dewe Rogerson

Agnès Villeret - Tel: +33 (0)1 53 32 78 95 - agnes.villeret@citigate.fr

Matthieu Pirouelle - Tel : +33 (0)1 53 32 84 77 - matthieu.pirouelle@citigate.fr

Public information

Copies of the Prospectus are available free of charge from the Company and from the Lead Manager and Bookrunner and the Joint-Lead Manager. The Prospectus may be viewed on the websites of the Company (www.ab-science.com) and the AMF (www.amf-france.org). The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 3 avenue George V, 75008 Paris. The attention of investors is drawn to Section 4, "Risk Factors", contained in the Document de base registered with the AMF, the update of such Document de base filed with the AMF and to Section 2 "Risk Factors" contained in the Note d'opération.

About AB SCIENCE

Founded in 2001, AB Science is a pharmaceutical company dedicated to the discovery, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules, whose action consists of modifying the signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicine. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules including masitinib, a lead compound that has already been registered in veterinary medicine in Europe, and is pursuing three on-going phase 3 studies in human medicine in pancreatic cancer, GIST and mastocytosis.

More information on AB Science's website: www.ab-science.com.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: www.nyx.com.